Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Onconetix (ONCO) EBT (2023 - 2025)

Historic EBT for Onconetix (ONCO) over the last 3 years, with Q3 2025 value amounting to -$8.8 million.

  • Onconetix's EBT fell 12616.32% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.1 million, marking a year-over-year increase of 325.64%. This contributed to the annual value of -$59.7 million for FY2024, which is 5962.73% down from last year.
  • Latest data reveals that Onconetix reported EBT of -$8.8 million as of Q3 2025, which was down 12616.32% from -$2.4 million recorded in Q2 2025.
  • Onconetix's EBT's 5-year high stood at -$2.4 million during Q2 2025, with a 5-year trough of -$30.4 million in Q4 2024.
  • Over the past 3 years, Onconetix's median EBT value was -$8.5 million (recorded in 2025), while the average stood at -$10.6 million.
  • As far as peak fluctuations go, Onconetix's EBT plummeted by 29485.58% in 2024, and later skyrocketed by 8335.82% in 2025.
  • Onconetix's EBT (Quarter) stood at -$22.4 million in 2023, then plummeted by 35.74% to -$30.4 million in 2024, then surged by 71.06% to -$8.8 million in 2025.
  • Its last three reported values are -$8.8 million in Q3 2025, -$2.4 million for Q2 2025, and -$8.5 million during Q1 2025.